Article
Neurosciences
Yijie Lai, Yunhai Song, Daoqing Su, Linbin Wang, Chencheng Zhang, Bomin Sun, Jorik Nonnekes, Bastiaan R. Bloem, Dianyou Li
Summary: Our study reveals the potential effectiveness of GPi-DBS in treating camptocormia in PD patients, showing significant improvement in patients' postural deformity. Pre-surgical TCC angle, levodopa responsiveness of the TCC angle, and structural connectivity from volume of tissue activated to somatosensory cortex are closely associated with improvement in the TCC angle.
NPJ PARKINSONS DISEASE
(2021)
Article
Neurosciences
Matthew Bernardinis, S. Farokh Atashzar, Rajni Patel, Mandar S. Jog
Summary: This study investigated the effect of Parkinson's disease and common therapies on vision-based perception of motion. The results showed that individuals with PD displayed significant perceptual impairments compared to controls, with impairments increasing with disease progression. Levodopa and DBS use did not significantly impact absolute displacement perception. Abnormal visual processing in PD may contribute to sensory-based impairments such as bradykinesia and visuospatial deficits.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Health Care Sciences & Services
Daniel van Poppelen, Annelie N. M. Tromp, Rob M. A. de Bie, Joke M. Dijk
Summary: Based on a retrospective case series and literature review, it was found that patients with Parkinson's disease who have persisting medication related motor response fluctuations despite DBS or CLI treatment may benefit from an additional or alternative treatment with either CLI or DBS.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Clinical Neurology
Francesco Cavallieri, Valerie Fraix, Francesco Bove, Delia Mulas, Manuela Tondelli, Anna Castrioto, Paul Krack, Sara Meoni, Emmanuelle Schmitt, Eugenie Lhommee, Amelie Bichon, Pierre Pelissier, Eric Chevrier, Andrea Kistner, Eric Seigneuret, Stephan Chabardes, Elena Moro
Summary: This study identified preoperative predictors of long-term motor outcome in PD patients undergoing bilateral STN-DBS, with frontal lobe dysfunction, disease severity in the off-medication condition, and the presence of vascular changes on neuroimaging being the main predictors. Short-term motor outcome after STN-DBS was predicted by preoperative levodopa response, tremor dominant phenotype, baseline frontal score, and off-medication MDS-UPDRS part III scores.
ANNALS OF NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Annalisa Gessani, Francesco Cavallieri, Valentina Fioravanti, Isabella Campanini, Andrea Merlo, Giulia Di Rauso, Benedetta Damiano, Sara Scaltriti, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Alessandro Fraternali, Annibale Versari, Giuseppe Biagini, Valerie Fraix, Serge Pinto, Elena Moro, Carla Budriesi, Franco Valzania
Summary: This study evaluated the long-term effects of bilateral STN-DBS on speech in advanced PD patients. The results showed that speech intelligibility remained at the same level as preoperative values in the long-term, and STN-DBS led to a significant improvement in speech intelligibility in the postoperative assessment.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Aurangzeb Kalhoro, Abdul Sattar M. Hashim
Summary: The study aimed to assess the effectiveness and accuracy of deep brain stimulation in Parkinsonian Disease. The results showed that deep brain stimulation can improve tremors, dyskinesias, rigidity, motor fluctuations, and bradykinesia in Parkinson's patients, but it is unlikely to benefit autonomic dysfunction and cognitive disorders. It is an expensive treatment compared to other methods, but it is reversible.
PAKISTAN JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Clinical Neurology
Marina Picillo, Onanong Phokaewvarangkul, Yu-Yan Poon, Cameron C. McIntyre, Sinem Balta Beylergil, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
Summary: This study compared the efficacy and safety of levodopa versus dopamine agonist monotherapy after deep brain stimulation in Parkinson's disease. Results showed that in short- and mid-term follow-up, more than half of patients were able to safely continue monotherapy, with levodopa patients having a higher likelihood. In the long term, only a minority of patients were able to maintain levodopa monotherapy, while dopamine agonist monotherapy was not well tolerated.
MOVEMENT DISORDERS
(2021)
Review
Neurosciences
Caroline Moreau, Tiphaine Rouaud, David Grabli, Isabelle Benatru, Philippe Remy, Ana-Raquel Marques, Sophie Drapier, Louise-Laure Mariani, Emmanuel Roze, David Devos, Gwendoline Dupont, Matthieu Bereau, Margherita Fabbri
Summary: Parkinson's disease is expected to have a significant increase in prevalence in Europe, but there is a shortage of neurologists who can provide expert care. The demand from patients for symptom control and therapeutic education is increasing, and innovative tools are needed to help doctors and patients monitor the disease and adapt treatment in their daily lives. Body-worn sensors have been proposed to monitor Parkinsonian symptoms, but their precise scope of use in routine care needs to be clarified.
NPJ PARKINSONS DISEASE
(2023)
Article
Multidisciplinary Sciences
Annalisa Gessani, Francesco Cavallieri, Valentina Fioravanti, Isabella Campanini, Andrea Merlo, Giulia Di Rauso, Benedetta Damiano, Sara Scaltriti, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Alessandro Fraternali, Annibale Versari, Giuseppe Biagini, Valerie Fraix, Serge Pinto, Elena Moro, Carla Budriesi, Franco Valzania
Summary: This study aimed to evaluate the long-term effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on speech in advanced Parkinson's Disease (PD) patients. The results showed that speech intelligibility stayed at the same level as preoperative values in the long-term follow-up. However, there was a significant acute improvement of speech intelligibility in the postoperative assessment.
SCIENTIFIC REPORTS
(2023)
Article
Clinical Neurology
Alberto J. Espay, Robert A. Hauser, Rohit Dhall, Sandeep Thakkar, Leslie Cloud, Leonid Zeitlin, Ghazal Banisadr, Stanley Fisher, Hester Visser
Summary: In this open-label extension of a phase 3 study, IPX203 demonstrated a favorable safety profile and sustained efficacy similar to the double-blind study. Improvements in efficacy were maintained throughout the trial, and adverse events were mostly mild or moderate and occurred within the first 90 days of treatment.
MOVEMENT DISORDERS
(2023)
Article
Health Care Sciences & Services
Valentina Leta, Haidar S. Dafsari, Anna Sauerbier, Vinod Metta, Nataliya Titova, Lars Timmermann, Keyoumars Ashkan, Michael Samuel, Eero Pekkonen, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Miriam Parry, Daniel J. van Wamelen, K. Ray Chaudhuri
Summary: Currently, device-aided therapies for advanced Parkinson's disease primarily focus on motor symptoms, with non-motor symptoms often only considered as possible exclusion criteria. However, differential effects on specific non-motor symptoms among these therapies have emerged, suggesting potential clinical implications. It is suggested that non-motor symptoms should be used as an additional criterion alongside motor symptoms to provide personalized therapy for advanced PD.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Clinical Neurology
Francesco Cavallieri, Annalisa Gessani, Andrea Merlo, Isabella Campanini, Carla Budriesi, Valentina Fioravanti, Giulia Di Rauso, Alberto Feletti, Benedetta Damiano, Sara Scaltriti, Noemi Guagnano, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Annette Puzzolante, Giuseppe Vannozzi, Elena Bergamini, Giacomo Pavesi, Valerie Fraix, Sara Meoni, Alessandro Fraternali, Annibale Versari, Mirco Lusuardi, Giuseppe Biagini, Serge Pinto, Elena Moro, Franco Valzania
Summary: This study evaluates correlations between speech and gait parameters in advanced Parkinson's disease patients under different medication and subthalamic nucleus deep brain stimulation conditions. The results show that patients who spoke louder had greater trunk acceleration during gait, and patients with poorer voice quality performed worse in the sit to stand and gait phases of the iTUG. Conversely, patients with higher speech rate performed well in the turning and walking phases of the iTUG.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Neurosciences
Francesc Valldeoriola, Maria Jose Catalan, Francisco Escamilla-Sevilla, Eric Freire, Jesus Olivares, Esther Cubo, Diego Santos Garcia, Matilde Calopa, Pablo Martinez-Martin, Juan Carlos Parra, Gloria Arroyo, Jose Matias Arbelo
Summary: LCIG has shown significant improvement in quality of life, motor and non-motor symptoms, emotional well-being, and treatment satisfaction in patients with Advanced Parkinson's Disease. Improvement in patient QoL is associated with improvements in various symptoms, while improvements in caregivers' QoL or burden do not necessarily correspond.
NPJ PARKINSONS DISEASE
(2021)
Article
Clinical Neurology
Diana A. Olszewska, Alfonso Fasano, Renato P. Munhoz, Carolina Candelaria Ramirez Gomez, Anthony E. Lang
Summary: This retrospective cohort study aimed to investigate the difference in the time between initial levodopa and dopamine agonist (DA) treatment and the development of disabling motor complications (MCs) in Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS). The results showed no significant difference in the duration from the first treatment to DBS assessment or surgery between patients who received levodopa and those who received a DA.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Chunguang Chu, Shang Liu, Naying He, Zhitong Zeng, Jiang Wang, Zhen Zhang, Kristina Zeljic, Odin van der Stelt, Bomin Sun, Fuhua Yan, Chen Liu, Dianyou Li, Chencheng Zhang
Summary: Aberrant dynamic switches between internal brain states are believed to underlie motor dysfunction in Parkinson's disease. Deep brain stimulation of the subthalamic nucleus is a well-established treatment for the motor symptoms of Parkinson's disease, yet it remains poorly understood how subthalamic stimulation modulates the whole-brain intrinsic motor network state dynamics.
